Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan

Takeda

Status and phase: Completed; Phase 3; Phase 2

Conditions: Type 2 Diabetes Mellitus

Treatments: Drug: Alogliptin and metformin; Drug: Metformin

Study type: Interventional

Funder types: Industry

Identifiers

NCT01318109

U1111-1119-6303 (Registry Identifier)

UMIN000001394 (Registry Identifier)

JapicCTI-080629 (Registry Identifier)

SYR-322/CCT-006

Details and patient eligibility

About

The purpose of this study was evaluate the efficacy and safety of alogliptin, once dairy (QD) combined with metformin taken twice daily (BID) or three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.

Full description

Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.

Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.

The present study was planned to evaluate the efficacy and safety of alogliptin as an add-on to metformin in type 2 diabetic patients who have uncontrolled blood glucose despite treatment with metformin as well as diet and exercise therapies.

Enrollment: 288 patients

Sex: All

Ages: 26 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Had been taking metformin at a stable dose regimen (500 mg/day twice daily after meal or 750 mg/day three times daily after meal) for at least 12 weeks prior to the initiation of the treatment period (Week 0).
2. Had an glycosylated hemoglobin (HbA1c) of 6.5% or more and below 10.0% at 8 weeks after the initiation of the observation period (Week -4).
3. Had an HbA1c difference between 4 weeks after the initiation of the observation period (Week -8) and 8 weeks after the initiation of the observation period (Week -4) being within 10.0%* of the value at 4 weeks after the initiation of the observation period (Week -8) (*rounded off to the first decimal place).
4. Was receiving specific diet and exercise (if any) therapies during the observation period.

Exclusion criteria

1. Had taken other diabetic medications than metformin within 12 weeks before the initiation of the treatment period (Week 0).
2. With a history or symptoms of lactic acidosis.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

288 participants in 3 patient groups

Alogliptin 12.5 mg QD and metformin 500mg BID or 750mg TID

Active Comparator group

Treatment:

Drug: Alogliptin and metformin

Drug: Alogliptin and metformin

Alogliptin 25mg QD and metformin 500mg BID or 750mg TID

Active Comparator group

Treatment:

Drug: Alogliptin and metformin

Drug: Alogliptin and metformin

Metformin 500mg BID or 750mg TID

Active Comparator group

Treatment:

Drug: Metformin